The core distinction
The gut has two things that antibiotics damage: the microbial community, and the mucosal environment that community inhabits. Probiotics address the first. TumGard addresses the second. This is not a marketing framing — it reflects how the two interventions work mechanistically.
What probiotics do after antibiotics
Reseeding: LGG and S. boulardii introduce commensal-compatible bacteria that colonise available niches in the depleted gut, competing against gram-negative opportunists and beginning community restoration.
AAD and C.diff prevention: The strongest clinical evidence for any post-antibiotic supplement. ~42% AAD reduction (LGG), ~60% C.diff reduction (LGG). S. boulardii provides similar effect sizes with the advantage of yeast-based antibiotic survival.
Butyrate recovery: As probiotic populations establish and provide the substrate for SCFA producers, butyrate production gradually recovers — restoring colonocyte energy supply and tight junction integrity.
What probiotics do not do: They do not directly inhibit NF-kB from gram-negative LPS expansion — the inflammatory pathway that drives mucosal damage and EGFR/ERK suppression. They do not directly activate EGFR/ERK mucosal repair.
What TumGard does after antibiotics
NF-kB inhibition (quercetin): As antibiotic dysbiosis depletes commensals and gram-negative organisms expand, LPS release activates NF-kB in intestinal epithelial cells. Quercetin inhibits NF-kB via IκB stabilisation — reducing the inflammatory cytokine cascade (IL-8, TNF-α) that causes mucosal damage and EGFR/ERK suppression independently of microbiome recovery.
EGFR/ERK mucosal repair (glabridin): Directly activates the mucosal cell regeneration pathway in gastric and intestinal lining — rebuilding the barrier integrity that butyrate loss has degraded. This runs on a 60–90 day cycle that is independent of (and complementary to) the microbiome recovery timeline.
What TumGard does not do: It does not reseed the microbiome, prevent C.diff colonisation, or provide butyrate. The microbial community recovery requires probiotics.
Direct comparison
| Function | Probiotics (LGG/S.boulardii) | TumGard |
|---|---|---|
| Microbiome reseeding | ✓ Yes — primary mechanism | ✗ Not mechanism |
| C.diff and AAD prevention | ✓ ~42–60% reduction | ✗ Not mechanism |
| NF-kB inhibition from LPS | ✗ Not mechanism | ✓ Quercetin IκB stabilisation |
| EGFR/ERK mucosal repair | ✗ Not mechanism | ✓ Glabridin activation |
| H. pylori urease inhibition | ✗ Not mechanism | ✓ Quercetin + myricetin |
| Duration of use | During + 8–12 weeks post-course | 60–90 day repair cycle |
| Timing during course | 2h from antibiotic doses (LGG); anytime (S.b.) | Anytime — no antibiotic interaction |
The H. pylori eradication patient — why both matter most here
The H. pylori eradication patient has pre-existing gastric mucosal damage (NF-kB active, EGFR/ERK suppressed) in addition to the microbiome collapse from eradication triple therapy. The eradication removes the bacterial source of NF-kB activation — but the mucosal damage it caused, and the dysbiosis NF-kB from gram-negative expansion, persist. Probiotics begin restoring the microbiome community. TumGard continues addressing the NF-kB inflammation from gram-negative LPS and directly activates the EGFR/ERK repair that H. pylori had suppressed. Both tools, used simultaneously, address the full damage profile.
The complete protocol
During the course: S. boulardii (anytime) or LGG (2h from doses). TumGard (anytime). Prebiotic fibre with meals.
Weeks 1–4 post-course: Continue LGG (no timing restriction). Continue TumGard. Gradually increase prebiotic fibre. Add fermented foods if tolerated.
Weeks 4–12 post-course: Continue LGG until 8–12 weeks. Continue TumGard for 60–90 day repair cycle total. H. pylori eradication patients: TumGard full 90 days post-eradication.
References
- Szajewska H et al. Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children. Alimentary Pharmacology & Therapeutics. 2015;42(10):1149–1157. PMID 26365980. LGG meta-analysis — ~42% AAD reduction, ~60% C.diff reduction. The evidence base for probiotic mechanisms in this comparison.
- Ye YN et al. Licorice flavonoids and gastric mucosal repair via EGFR/ERK pathway. Journal of Ethnopharmacology. 2023;302:115866. PMID 36842733. Glabridin EGFR/ERK activation — the mucosal repair mechanism that distinguishes TumGard's role from probiotics'.
- Xiao ZP et al. Quercetin as inhibitor of H. pylori urease and NF-kB pathway. European Journal of Medicinal Chemistry. 2006;41(4):476–82. PMID 16887239. Quercetin NF-kB inhibition — the inflammatory pathway that LPS from gram-negative expansion activates and that probiotics do not address.
- Sokol H et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium. PNAS. 2008;105:16731–16736. PMID 19066305. Establishes the keystone commensal's anti-inflammatory role — the organism probiotics are reseeding toward and TumGard is creating the environment for.